EIF2B5

Across TCGA pan-cancer cohorts, EIF2B5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EIF2B5 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher EIF2B5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EIF2B5 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LIHC, DLBC, and BLCA are the cancer types where EIF2B5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.062	0.556	<.001	15	view →
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
BLCA	OS	Median	II,III,IV	1.000	0.599	.015	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EIF2B5–LIHC (DFS)

Open the LIHC breakdown →